Skip to main navigation Skip to search Skip to main content

Cell therapy for lung diseases report from an NIH-NHLBI workshop, november 13-14, 2012

  • Michael A. Matthay
  • , Piero Anversa
  • , Jahar Bhattacharya
  • , Bruce K. Burnett
  • , Harold A. Chapman
  • , Joshua M. Hare
  • , Derek J. Hei
  • , Andrew M. Hoffman
  • , Stella Kourembanas
  • , David H. McKenna
  • , Luis A. Ortiz
  • , Harald C. Ott
  • , William Tente
  • , Bernard Thebaud
  • , Bruce C. Trapnell
  • , Daniel J. Weiss
  • , Jason X.J. Yuan
  • , Carol J. Blaisdell*
  • *Corresponding author for this work
  • University of California
  • Harvard University
  • Columbia University
  • Duke University School of Medicine
  • Miller School of Medicine
  • University of Wisconsin-Madison
  • Tufts University
  • University of Minnesota-Twin Cities
  • University of Pittsburgh
  • Massachusetts General Hospital
  • HUMACYTE, INC.
  • University of Ottawa
  • Cincinnati Children's Hospital Medical Center
  • University of Vermont
  • University of Illinois at Chicago
  • National Institutes of Health

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanismsof cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.

Original languageEnglish
Pages (from-to)370-375
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume188
Issue number3
DOIs
StatePublished - 1 Aug 2013
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Epithelial and endothelial progenitor cells
  • Lung stem cells
  • Mesenchymal stromal (stem) cells

Fingerprint

Dive into the research topics of 'Cell therapy for lung diseases report from an NIH-NHLBI workshop, november 13-14, 2012'. Together they form a unique fingerprint.

Cite this